SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Elder Pharmaceuticals shines on creating joint venture with KOSE Corporation of Japan

Elder Pharmaceuticals Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 532322 | NSE: ELDERPHARM

07 Mar 2013 Evaluate

Elder Pharmaceuticals is currently trading at Rs 334.45, up by 14.35 points or 4.48% from its previous closing of Rs 320.10 on the BSE.

The scrip opened at Rs 328.00 and has touched a high and low of Rs 339.00 and Rs 328.00 respectively. So far 12567 shares were traded on the counter.

The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 474.00 on 05-Dec-2012 and a 52 week low of Rs 267.05 on 16-Aug-2012.

Last one week high and low of the scrip stood at Rs 339.00 and Rs 301.60 respectively. The current market cap of the company is Rs 657.39 crore.

The promoters holding in the company stood at 39.89% while Institutions and Non-Institutions held 22.92% and 37.18% respectively.

Elder Pharmaceuticals, a leading pharmaceuticals company in India, having consolidated turnover in excess of Rs 1,350 crore for FY12 and ranked 27 amongst Indian pharmaceutical companies as per IMS Report October 2012, has agreed to establish a Joint Venture Company (JVC) with KOSE Corporation (KOSE) with the provisional name of KOSE Elder (India).

On March 6, 2013 both the companies have, subject to the fulfillment of certain terms and conditions finalized terms and conditions of the joint venture contract. The agreement stipulates that KOSE will focus on the Indian market, through the JVC for manufacturing and selling cosmetics in India. KOSE will hold 60% and Elder to hold 40% in the proposed JV. Elder has successfully established and run subsidiaries abroad and with alliance with KOSE, Elder is foraying into its maiden joint Venture arrangement in India with a Japanese company.

KOSE’s key means of advancing into overseas markets up to now has been to export from Japan only those of its existing brand products that matched the requirements of the target country’s market, but in India, where culture and tastes are very different, they have considered it essential to undertake strategic and business planning tailored to the region, and are proceeding with investigations through agreements with local enterprises that are familiar with the markets.

Elder Pharmaceuticals (EPL) has around six manufacturing units in India, all as per international standards. Post increasing its stake in Elder Biomeda AD and Neutrahealth PLC, EPL also has access to the manufacturing units of these companies in Bulgaria and Birmingham, UK respectively coupled with distribution network and brands of the same.

Elder Pharma Share Price

Not Listed

View Price Chart

Peers

Company Name	CMP
Sun Pharma Inds.	1675.20
Dr. Reddys Lab	1235.40
Cipla	1238.30
Zydus Lifesciences	942.55
Lupin	2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

PROPRIETARY FRAMEWORK

Portfolio
Architecture >
Stock Picking.

Stop managing a collection of "tips." Access the ABC Framework to build a portfolio that survives cycles and compounds wealth.

Core for Stability

Booster for Alpha

Amplifier for Exponential Wealth

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Access Sapphire ABC Strategy →

Limited Capacity for New Fiduciary Partners

Elder Pharmaceuticals shines on creating joint venture with KOSE Corporation of Japan

MoneyWorks4Me Premium

Follow us at

MoneyWorks4Me

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.